VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. - Lu H; Dietsch GN; Matthews MA; Yang Y; Ghanekar S; Inokuma M; Suni M; Maino VC; Henderson KE; Howbert JJ; Disis ML; Hershberg RM (Clinical cancer research : an official journal of the American Association for Cancer Research, 2012)